Chengdu Kanghua Biological Products (300841.SZ): Recombinant hexavalent Norovirus vaccine obtains US FDA approval to enter clinical research.

18:50 07/09/2023

Chengdu Kanghua Biological Products (300841.SZ) announced that the company has received a notification from the US Food and Drug Administration (FDA), approving the company's recombinant hexavalent rotavirus vaccine for clinical research in the United States. The recombinant hexavalent rotavirus vaccine is applicable for the prevention of rotavirus infection and acute gastroenteritis caused by rotavirus. Rotavirus is one of the main pathogens causing acute gastroenteritis outbreaks and epidemics in people of all age groups worldwide. Currently, there are no approved therapeutic drugs or preventive vaccine products for rotavirus available globally.

National Energy Administration: Nationwide electricity market transaction volume grew by 7.2% year-on-year from January to September.

AI profitability validation is coming: Performance will debunk the bubble theory, this week's big five tech giants' financial reports will set the tone for the next wave.

DC Holdings (00861) Kjet and UQI signed a strategic cooperation agreement to jointly build a new intelligent logistics ecosystem.

National Energy Administration: Nationwide electricity market transaction volume grew by 7.2% year-on-year from January to September.

AI profitability validation is coming: Performance will debunk the bubble theory, this week's big five tech giants' financial reports will set the tone for the next wave.

DC Holdings (00861) Kjet and UQI signed a strategic cooperation agreement to jointly build a new intelligent logistics ecosystem.